Holen Sie sich die Stockscreener-App
29.21
0.82%
-0.285
Schlusskurs vom Vortag:
$29.50
Offen:
$28.67
24-Stunden-Volumen:
411.34K
Relative Volume:
0.42
Marktkapitalisierung:
$1.73B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-97.21M
KGV:
-15.83
EPS:
-1.8459
Netto-Cashflow:
$-71.82M
1W Leistung:
+3.31%
1M Leistung:
+6.00%
6M Leistung:
+39.65%
1J Leistung:
+49.12%
1-Tages-Spanne:
$28.01
$29.45
1-Wochen-Bereich:
$27.98
$30.04
52-Wochen-Spanne:
$13.30
$30.22
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Firmenname
Enliven Therapeutics Inc
Sektor
Branche
Telefon
720-647-8519
Adresse
6200 LOOKOUT ROAD, BOULDER
Compare ELVN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
29.16 | 1.75B | 0 | -97.21M | -71.82M | -1.8459 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.89 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.55 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.65 | 46.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.07 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
295.86 | 34.79B | 4.98B | 69.60M | 525.67M | 0.5198 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-16 | Eingeleitet | Goldman | Buy |
| 2024-12-13 | Eingeleitet | BTIG Research | Buy |
| 2024-09-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-06-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-09 | Eingeleitet | Mizuho | Buy |
| 2023-03-29 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Enliven Therapeutics Inc Aktie (ELVN) Neueste Nachrichten
ELVN SEC FilingsEnliven Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ELVN Should I Buy - Intellectia AI
Enliven Therapeutics, Inc. (ELVN) Stock Analysis: Exploring a 37.94% Upside Potential in Biotech - DirectorsTalk Interviews
Biotech fireside chat: Enliven Therapeutics at TD Cowen event - Stock Titan
Insider Trends: Can Enliven Therapeutics Inc disrupt its industryJuly 2025 Recap & AI Powered Market Entry Strategies - baoquankhu1.vn
ELVN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
(ELVN) Risk Channels and Responsive Allocation - Stock Traders Daily
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Enliven Therapeutics, Inc. (ELVN) Stock Analysis: A Biotech Gem with 58% Upside and Strong Buy Ratings - DirectorsTalk Interviews
Enliven Therapeutics (NASDAQ:ELVN) Director Sells $32,201.40 in Stock - MarketBeat
Heyman, Enliven Therapeutics director, sells $32k in stock By Investing.com - Investing.com Canada
Plan-based 1,230-share sale by Enliven (ELVN) director disclosed - Stock Titan
Investment Report: Is SAIL forming a double bottomInsider Buying & Weekly Momentum Stock Picks - baoquankhu1.vn
Market Catalysts: Is Enliven Therapeutics Inc a speculative investment2025 Institutional Moves & Verified Entry Point Detection - baoquankhu1.vn
Gains Report: Is First Internet Bancorp showing insider buyingJuly 2025 Action & High Conviction Investment Ideas - baoquankhu1.vn
Stock Market Recap: How sensitive is Enliven Therapeutics Inc to inflationJuly 2025 Rallies & Safe Capital Investment Plans - baoquankhu1.vn
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Short Interest Down 14.1% in January - MarketBeat
Can Enliven Therapeutics Inc disrupt its industryQuarterly Portfolio Summary & Breakout Confirmation Alerts - baoquankhu1.vn
Richard Heyman plans Enliven (NASDAQ: ELVN) Rule 144 stock sale - Stock Titan
Will Enliven Therapeutics Inc. benefit from rising consumer demandJuly 2025 EndofMonth & Free Expert Verified Stock Movement Alerts - mfd.ru
What drives Enliven Therapeutics Inc.’s stock priceJuly 2025 Breakouts & Growth Focused Stock Reports - mfd.ru
Is Enliven Therapeutics Inc. stock attractive for income investorsProduct Launch & Daily Stock Trend Watchlist - mfd.ru
(ELVN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
History Review: Can Enliven Therapeutics Inc disrupt its industryWeekly Market Outlook & Smart Allocation Stock Tips - baoquankhu1.vn
Candriam S.C.A. Raises Stock Position in Enliven Therapeutics, Inc. $ELVN - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Insider Sells $145,200.00 in Stock - MarketBeat
Lyssikatos, Enliven Therapeutics CSO, sells $145k in shares By Investing.com - Investing.com UK
Lyssikatos, Enliven Therapeutics CSO, sells $145k in shares - Investing.com
Aug Technicals: What drives Enliven Therapeutics Incs stock priceJuly 2025 Recap & Stepwise Trade Signal Implementation - baoquankhu1.vn
Bear Alert: Will AdvanSix Inc stock hit new highs in YEARQuarterly Earnings Summary & Safe Entry Trade Reports - baoquankhu1.vn
Enliven Therapeutics (NASDAQ:ELVN) Sets New 1-Year HighWhat's Next? - MarketBeat
Aug Highlights: How sensitive is Enliven Therapeutics Inc to inflation2025 Performance Recap & Breakout Confirmation Trade Signals - baoquankhu1.vn
Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k - AOL.com
Heron Therapeutics (NASDAQ:HRTX) & Enliven Therapeutics (NASDAQ:ELVN) Head to Head Contrast - Defense World
Update Report: Can Enliven Therapeutics Inc disrupt its industryPortfolio Gains Report & Fast Gaining Stock Reports - baoquankhu1.vn
Assessing Enliven Therapeutics (ELVN) Valuation After CSO Share Sale And Early Leukemia Trial Progress - Sahm
Enliven Therapeutics Executive Sells 20,000 Shares - Intellectia AI
Enliven Therapeutics, Inc. (ELVN) Stock Analysis: A Biotech Pioneer with 61% Potential Upside - DirectorsTalk Interviews
Enliven Therapeutics CFO sells $22,524 in stock - MSN
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Aug Sectors: What is DATSs valuation compared to sectorJuly 2025 Big Picture & High Accuracy Investment Signals - baoquankhu1.vn
Market Outlook: Is Enliven Therapeutics Inc attractive for institutional investorsStop Loss & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Joseph Lyssikatos Sells 20,000 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock - Defense World
Janux Therapeutics Inc (JANX) Gets a Buy from JonesTrading - The Globe and Mail
Enliven Therapeutics director Heyman sells $32,901 in stock By Investing.com - Investing.com South Africa
Day Trade: What hedge funds are buying TSLA2025 Major Catalysts & Technical Buy Zone Confirmations - baoquankhu1.vn
Lyssikatos, Enliven Therapeutics CSO, sells $535k in ELVN stock By Investing.com - Investing.com Canada
Enliven Therapeutics (NASDAQ:ELVN) Director Sells 1,230 Shares - MarketBeat
Finanzdaten der Enliven Therapeutics Inc-Aktie (ELVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.19%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):